Opdualag is a fixed-dose immunotherapy combination of nivolumab and relatlimab-rmbw for unresectable or metastatic melanoma. It combines PD-1 and LAG-3 checkpoint blockade to enhance T-cell activation compared with either antibody alone. The FDA first approved Opdualag on March 18, 2022.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07644312 |
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG |
NOT_YET_RECRUITING | PHASE2 |
| NCT06319196 |
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma |
RECRUITING | PHASE2 |
| NCT06208657 |
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT05970497 |
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
